Cargando…

Predictors of adherence and persistence to disease-modifying therapies in Multiple Sclerosis

BACKGROUND AND AIMS: In multiple sclerosis (MS), non-adherence/non-persistence is related to suboptimal response to treatment, including disease relapses and the need for more expensive healthcare. The aim of this study was to identify predictors related to adherence to disease modifying therapies (...

Descripción completa

Detalles Bibliográficos
Autores principales: Zanga, Gisela, Drzewiscki, Estefania, Tagliani, Paula, Smietniansky, Maximiliano, Esnaola y Rojas, Maria M., Caruso, Diego
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8495537/
https://www.ncbi.nlm.nih.gov/pubmed/34630632
http://dx.doi.org/10.1177/17562864211031099
_version_ 1784579575520428032
author Zanga, Gisela
Drzewiscki, Estefania
Tagliani, Paula
Smietniansky, Maximiliano
Esnaola y Rojas, Maria M.
Caruso, Diego
author_facet Zanga, Gisela
Drzewiscki, Estefania
Tagliani, Paula
Smietniansky, Maximiliano
Esnaola y Rojas, Maria M.
Caruso, Diego
author_sort Zanga, Gisela
collection PubMed
description BACKGROUND AND AIMS: In multiple sclerosis (MS), non-adherence/non-persistence is related to suboptimal response to treatment, including disease relapses and the need for more expensive healthcare. The aim of this study was to identify predictors related to adherence to disease modifying therapies (DMTs) in a cohort of Argentinian MS patients. METHODS: We conducted a cross-sectional study at the National Medical Care Program from Argentina. MS patients with at least one claim for a DMT from 1 January 2017 to 1 October 2017 were identified. A telephone survey was performed to assess clinical and demographic factors. The medication possession ratio (MPR) was used to estimate adherence; MPR <80% defined non-adherence. Associations were studied using a logistic regression model. RESULTS: Our database included 648 MS patients. A total of 360 patients (60% females, mean age 55.3 years) accepted to participate. Of these, 308 (85.5%) patients were receiving DMT at the time of the survey. Some 198 (63.7%) were receiving injectable therapies. Optimal adherence was 47.7%. Adherence was associated with oral medication [odds ratio (OR) 1.83 95% confidence interval (CI) 1.13–3.00, p = 0.014]. A factor related to oral drugs was higher educational level (OR 2.86 95%CI 1.41–5.81, p = 0.004). CONCLUSION: This real-world study showed better adherence and persistence on treatment with oral therapies in MS patients in Argentina.
format Online
Article
Text
id pubmed-8495537
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-84955372021-10-08 Predictors of adherence and persistence to disease-modifying therapies in Multiple Sclerosis Zanga, Gisela Drzewiscki, Estefania Tagliani, Paula Smietniansky, Maximiliano Esnaola y Rojas, Maria M. Caruso, Diego Ther Adv Neurol Disord Original Research BACKGROUND AND AIMS: In multiple sclerosis (MS), non-adherence/non-persistence is related to suboptimal response to treatment, including disease relapses and the need for more expensive healthcare. The aim of this study was to identify predictors related to adherence to disease modifying therapies (DMTs) in a cohort of Argentinian MS patients. METHODS: We conducted a cross-sectional study at the National Medical Care Program from Argentina. MS patients with at least one claim for a DMT from 1 January 2017 to 1 October 2017 were identified. A telephone survey was performed to assess clinical and demographic factors. The medication possession ratio (MPR) was used to estimate adherence; MPR <80% defined non-adherence. Associations were studied using a logistic regression model. RESULTS: Our database included 648 MS patients. A total of 360 patients (60% females, mean age 55.3 years) accepted to participate. Of these, 308 (85.5%) patients were receiving DMT at the time of the survey. Some 198 (63.7%) were receiving injectable therapies. Optimal adherence was 47.7%. Adherence was associated with oral medication [odds ratio (OR) 1.83 95% confidence interval (CI) 1.13–3.00, p = 0.014]. A factor related to oral drugs was higher educational level (OR 2.86 95%CI 1.41–5.81, p = 0.004). CONCLUSION: This real-world study showed better adherence and persistence on treatment with oral therapies in MS patients in Argentina. SAGE Publications 2021-10-05 /pmc/articles/PMC8495537/ /pubmed/34630632 http://dx.doi.org/10.1177/17562864211031099 Text en © The Author(s), 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
Zanga, Gisela
Drzewiscki, Estefania
Tagliani, Paula
Smietniansky, Maximiliano
Esnaola y Rojas, Maria M.
Caruso, Diego
Predictors of adherence and persistence to disease-modifying therapies in Multiple Sclerosis
title Predictors of adherence and persistence to disease-modifying therapies in Multiple Sclerosis
title_full Predictors of adherence and persistence to disease-modifying therapies in Multiple Sclerosis
title_fullStr Predictors of adherence and persistence to disease-modifying therapies in Multiple Sclerosis
title_full_unstemmed Predictors of adherence and persistence to disease-modifying therapies in Multiple Sclerosis
title_short Predictors of adherence and persistence to disease-modifying therapies in Multiple Sclerosis
title_sort predictors of adherence and persistence to disease-modifying therapies in multiple sclerosis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8495537/
https://www.ncbi.nlm.nih.gov/pubmed/34630632
http://dx.doi.org/10.1177/17562864211031099
work_keys_str_mv AT zangagisela predictorsofadherenceandpersistencetodiseasemodifyingtherapiesinmultiplesclerosis
AT drzewisckiestefania predictorsofadherenceandpersistencetodiseasemodifyingtherapiesinmultiplesclerosis
AT taglianipaula predictorsofadherenceandpersistencetodiseasemodifyingtherapiesinmultiplesclerosis
AT smietnianskymaximiliano predictorsofadherenceandpersistencetodiseasemodifyingtherapiesinmultiplesclerosis
AT esnaolayrojasmariam predictorsofadherenceandpersistencetodiseasemodifyingtherapiesinmultiplesclerosis
AT carusodiego predictorsofadherenceandpersistencetodiseasemodifyingtherapiesinmultiplesclerosis